Compare Levi Strauss & Co. (LEVI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs State Street SPDR S&P Biotech ETF — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.36% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LEVI | XBI | |
|---|---|---|
Market Cap | $7.31B | $10.11B |
Volume | 13,683,095 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $25.53 | $169.55 |
52-Week Low | $17.92 | $104.99 |
Typical Hold Time | 70 Days | 38 Days |
Enterprise Value | $8.86B | — |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for four consecutive quarters, including Q3 2026 EPS of $0.48 versus $0.36 expected. Financial health is robust with a net income margin of 8.83% and ROE of 25.76%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 results driven by denim demand trends.
The investment outlook is positive based on fundamentals and analyst sentiment, with a consensus price target of $29.00 implying significant upside. Risks include competitive pressures, recent cybersecurity incidents, and macroeconomic sensitivity. Wall Street maintains a strong buy consensus, supporting a favorable risk-reward profile for long-term investors.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
